Catalyst
Slingshot members are tracking this event:
Phase 3 clinical trial to evaluate 33A in combination with HMAs in previously untreated older AML patients is planned to begin by the third quarter of 2016.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 25, 2016
Occurred Source:
http://www.businesswire.com/news/home/20160525005203/en/Seattle-Genetics-Initiates-Pivotal-Phase-3-Trial
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
33a, Hmas, Aml, Acute Myeloid Leukemia, Mds-, Pyrrolobenzodiazepine
